Smoking outcome by psychiatric history after behavioral and varenicline treatment

Jennifer B. McClure, Gary E. Swan, Sheryl L Catz, Lisa Jack, Harold Javitz, Tim McAfee, Mona Deprey, Julie Richards, Susan M. Zbikowski

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Treatment outcomes were compared across smokers enrolled in the COMPASS cessation trial with (positive psychiatric history [PH+], n = 271) and without (PH-, n = 271) a diagnosis of PH based on medical record evidence of anxiety, depression, psychotic disorder, or bipolar disorder. Everyone received behavioral counseling plus varenicline and was followed for 6 months post quit date. PH+ smokers took varenicline for fewer days on average (59.4 vs. 68.5, p ≤ .01) but did not differ in their use of behavioral treatment. PH+ smokers were more likely to report anxiety and depression, but side-effect intensity ratings did not differ after adjusting for multiple comparisons. Overall, all side effects were rated as moderate intensity or less. Groups had similar 30-day abstinence rates at 6 months (31.5% PH+ vs. 35.4% PH-, p = .35). In sum, having a psychiatric diagnosis in this trial did not predict worse treatment outcome or worse treatment side effects.

Original languageEnglish (US)
Pages (from-to)394-402
Number of pages9
JournalJournal of Substance Abuse Treatment
Volume38
Issue number4
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Psychiatry
Anxiety
Smoking
Depression
Bipolar Disorder
Mental Disorders
Psychotic Disorders
Medical Records
Counseling
Varenicline

Keywords

  • Anxiety
  • Depression
  • Psychiatric illness
  • Side effects
  • Smoking cessation
  • Varenicline

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Phychiatric Mental Health
  • Medicine (miscellaneous)

Cite this

Smoking outcome by psychiatric history after behavioral and varenicline treatment. / McClure, Jennifer B.; Swan, Gary E.; Catz, Sheryl L; Jack, Lisa; Javitz, Harold; McAfee, Tim; Deprey, Mona; Richards, Julie; Zbikowski, Susan M.

In: Journal of Substance Abuse Treatment, Vol. 38, No. 4, 06.2010, p. 394-402.

Research output: Contribution to journalArticle

McClure, JB, Swan, GE, Catz, SL, Jack, L, Javitz, H, McAfee, T, Deprey, M, Richards, J & Zbikowski, SM 2010, 'Smoking outcome by psychiatric history after behavioral and varenicline treatment', Journal of Substance Abuse Treatment, vol. 38, no. 4, pp. 394-402. https://doi.org/10.1016/j.jsat.2010.03.007
McClure, Jennifer B. ; Swan, Gary E. ; Catz, Sheryl L ; Jack, Lisa ; Javitz, Harold ; McAfee, Tim ; Deprey, Mona ; Richards, Julie ; Zbikowski, Susan M. / Smoking outcome by psychiatric history after behavioral and varenicline treatment. In: Journal of Substance Abuse Treatment. 2010 ; Vol. 38, No. 4. pp. 394-402.
@article{1aaec34926e34a81a0570d14e82ceb94,
title = "Smoking outcome by psychiatric history after behavioral and varenicline treatment",
abstract = "Treatment outcomes were compared across smokers enrolled in the COMPASS cessation trial with (positive psychiatric history [PH+], n = 271) and without (PH-, n = 271) a diagnosis of PH based on medical record evidence of anxiety, depression, psychotic disorder, or bipolar disorder. Everyone received behavioral counseling plus varenicline and was followed for 6 months post quit date. PH+ smokers took varenicline for fewer days on average (59.4 vs. 68.5, p ≤ .01) but did not differ in their use of behavioral treatment. PH+ smokers were more likely to report anxiety and depression, but side-effect intensity ratings did not differ after adjusting for multiple comparisons. Overall, all side effects were rated as moderate intensity or less. Groups had similar 30-day abstinence rates at 6 months (31.5{\%} PH+ vs. 35.4{\%} PH-, p = .35). In sum, having a psychiatric diagnosis in this trial did not predict worse treatment outcome or worse treatment side effects.",
keywords = "Anxiety, Depression, Psychiatric illness, Side effects, Smoking cessation, Varenicline",
author = "McClure, {Jennifer B.} and Swan, {Gary E.} and Catz, {Sheryl L} and Lisa Jack and Harold Javitz and Tim McAfee and Mona Deprey and Julie Richards and Zbikowski, {Susan M.}",
year = "2010",
month = "6",
doi = "10.1016/j.jsat.2010.03.007",
language = "English (US)",
volume = "38",
pages = "394--402",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Smoking outcome by psychiatric history after behavioral and varenicline treatment

AU - McClure, Jennifer B.

AU - Swan, Gary E.

AU - Catz, Sheryl L

AU - Jack, Lisa

AU - Javitz, Harold

AU - McAfee, Tim

AU - Deprey, Mona

AU - Richards, Julie

AU - Zbikowski, Susan M.

PY - 2010/6

Y1 - 2010/6

N2 - Treatment outcomes were compared across smokers enrolled in the COMPASS cessation trial with (positive psychiatric history [PH+], n = 271) and without (PH-, n = 271) a diagnosis of PH based on medical record evidence of anxiety, depression, psychotic disorder, or bipolar disorder. Everyone received behavioral counseling plus varenicline and was followed for 6 months post quit date. PH+ smokers took varenicline for fewer days on average (59.4 vs. 68.5, p ≤ .01) but did not differ in their use of behavioral treatment. PH+ smokers were more likely to report anxiety and depression, but side-effect intensity ratings did not differ after adjusting for multiple comparisons. Overall, all side effects were rated as moderate intensity or less. Groups had similar 30-day abstinence rates at 6 months (31.5% PH+ vs. 35.4% PH-, p = .35). In sum, having a psychiatric diagnosis in this trial did not predict worse treatment outcome or worse treatment side effects.

AB - Treatment outcomes were compared across smokers enrolled in the COMPASS cessation trial with (positive psychiatric history [PH+], n = 271) and without (PH-, n = 271) a diagnosis of PH based on medical record evidence of anxiety, depression, psychotic disorder, or bipolar disorder. Everyone received behavioral counseling plus varenicline and was followed for 6 months post quit date. PH+ smokers took varenicline for fewer days on average (59.4 vs. 68.5, p ≤ .01) but did not differ in their use of behavioral treatment. PH+ smokers were more likely to report anxiety and depression, but side-effect intensity ratings did not differ after adjusting for multiple comparisons. Overall, all side effects were rated as moderate intensity or less. Groups had similar 30-day abstinence rates at 6 months (31.5% PH+ vs. 35.4% PH-, p = .35). In sum, having a psychiatric diagnosis in this trial did not predict worse treatment outcome or worse treatment side effects.

KW - Anxiety

KW - Depression

KW - Psychiatric illness

KW - Side effects

KW - Smoking cessation

KW - Varenicline

UR - http://www.scopus.com/inward/record.url?scp=77952237734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952237734&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2010.03.007

DO - 10.1016/j.jsat.2010.03.007

M3 - Article

VL - 38

SP - 394

EP - 402

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 4

ER -